ArticleResearch square2026
Point-of-care Diagnostic Framework for Fibromyalgia Using Integrated Vibrational Spectroscopy and Metabolomics.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Background: There is a critical need for objective diagnostic strategies for syndromes that rely on subjective questionnaires to ensure accurate and reliable diagnosis. Fibromyalgia (FM), one of the most common rheumatic disorders, remains particularly challenging to diagnose because of symptom overlap with related conditions, especially rheumatoid arthritis (RA). This exploratory study evaluated the feasibility of a combined spectroscopic-metabolomic workflow for distinguishing FM from RA and healthy controls (HC). Methods: Whole blood specimens were analyzed from 40 patients with FM, 20 patients with RA, and 10 HC participants. The analytical workflow combined portable Fourier-transform infrared (FTIR) spectroscopic fingerprinting with mass spectrometry (MS)-based metabolite identification. Potential confounding factors affecting analytical signatures were systematically evaluated, and alternative extraction protocols were compared. Methanol (MeOH) and methanol/1-butanol (MeOH/BuOH) extraction methods gave a good metabolome coverage and were selected for subsequent analyses. Soft independent modeling by class analogy (SIMCA) and partial least squares discriminant analysis (PLS-DA) were used for classification, while partial least squares regression (PLSR) was used to correlate FTIR spectral features with biologically relevant metabolites identified by MS. Results: SIMCA models demonstrated good classification between FM and HC, with interclass distances (ICD) exceeding 4.1 for MeOH extraction and 4.6 for MeOH/BuOH extraction. MS-based metabolomic analyses identified oligopeptides, inosine monophosphate, and signaling lipid molecules as major contributors to group differentiation, suggesting probable dysregulation of oxidative stress and inflammatory signaling pathways, as well as purine, amino acid, and free fatty acid metabolism. PLSR models showed strong correlations between FTIR spectral data and MS intensities, including inosine monophosphate, N-acylethanolamines (NAE), monoacylglycerols (MAG), N-fructosyl phenylalanine, N-fructosyl isoleucine, Ser-Phe, and N-acetylhistidylprolinamide (R ≥ 0.79; SECV ≤ 0.30). Conclusions: These findings demonstrate the potential of integrating rapid FTIR spectroscopic fingerprinting with MS-driven metabolomics to identify biologically relevant signatures associated with fibromyalgia. The strong classification performance and metabolite correlations support the potential translation of this diagnostic pipeline into a rapid, point-of-care approach for objective FM diagnosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.